---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-24-000073"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:58:52.025875+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics Q3 net loss narrows to $4.8M; FDA clinical hold on cadisegliatin continues

## Summary
- Net loss of $4.8M ($0.88/share) vs $6.7M ($3.19) in Q3 2023; nine-month net loss $14.8M.
- Cash $41.6M at Sep 30, 2024, up from $9.4M at Dec 31, 2023, boosted by private placement and ATM.
- R&D spend $3.2M (up from $2.8M) on higher indirect costs; G&A $3.3M (up from $2.5M) due to share-based and legal.
- Cadisegliatin program under FDA clinical hold since July 2024; company addressing basis for hold.
- No revenue in Q3 2024; YTD revenue $1.0M from prior periods.

## SEC filing metadata
- accession: 0001641489-24-000073
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000073/0001641489-24-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000073/vtvt-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-24-000073
- JSON: https://secwatch.observer/filing/0001641489-24-000073.json
- Plain text: https://secwatch.observer/filing/0001641489-24-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.